Table 1.
Characteristics of the CML patients on TKI medication involved in the study (n=86)
| Variables | n (%) |
|---|---|
| Sex, n (%) | |
| Male | 45 (52.3) |
| Female | 41 (47.7) |
| Agea (years) | |
| Mean (SD) | 57.8 (12.1) |
| Median | 59.0 |
| Range | 25.0–83.0 |
| Age at diagnosis (years) | |
| Mean (SD) | 52.7 (12.3) |
| Median | 52.0 |
| Range | 19.0–79.0 |
| Time from diagnosis (years) | |
| Mean (SD) | 5.1 (3.7) |
| Median | 4.0 |
| Range | 0.5–17.0 |
| TKI medication-related factors | |
| TKI medication, n (%) | |
| Imatinib | 68 (79.1) |
| Dasatinib | 9 (10.5) |
| Nilotinib | 9 (10.5) |
| Line, n (%) | |
| First | 47 (54.7) |
| Second | 25 (29.1) |
| Third | 13 (15.1) |
| Fourth | 1 (1.2) |
| Number of TKI doses per day, n (%) | |
| One | 72 (83.7) |
| Two | 14 (16.3) |
| Comorbidities (n) | |
| Mean | 1.6 |
| Median | 1 |
| Range | 0–8 |
| Other medications (n) | |
| Mean | 2.2 |
| Median | 2 |
| Range | 0–10 |
| Quality of Life Scoreb | |
| Mean | 1 |
| Median | 0 |
| Range | 0–5 |
| Patient-reported ADRs (n) | |
| Mean | 7 |
| Median | 6 |
| Range | 0–15 |
Notes:
a
At the time of adherence evaluation;
b
Range 0–6; score 0, best; score 6, worst.
Abbreviations: ADRs, adverse drug reactions; CML, chronic myeloid leukemia; SD, standard deviation; TKI, tyrosine kinase inhibitor.